As an example, the antibody used in this study, monoclonal antibody C225, has a high affinity for EGFR and has been shown to be efficacious in several types of cancer, particularly colorectal and head and neck cancers [30].
However, there is now an increased interest in GSIs as a potential treatment for hematological malignancies and cancer since they have been shown to be efficacious in several tumor models [29], [30].
In addition to leprosy, clofazimine has also been tested and found to be efficacious in several autoimmune diseases including lupus erythematosus [43], [44], Crohn's disease [45], ulcerative colitis [46], and pustular psoriasis [47].
For CRBSI-treatment, an ethanol-lock has been demonstrated to be efficacious in several observational studies.[15] [17] More recently, an ethanol-lock has also been studied for CRBSI-prevention.[18] [21] A major advantage of ethanol would be the broad antimicrobial spectrum without compromising future antibiotic treatment.
βHB has also been shown to be efficacious in several animal models of PD.
The concept of interrupting the myocardial reperfusion process with the angioplasty balloon to reduce myocardial IS (as assessed by different modalities, including cardiac biomarkers) has been demonstrated to be efficacious in several small-size studies evaluating STEMI patients undergoing PPCI [ 10, 19, 21, 26].
Both agents are efficacious in several other experimental arthritis models [ 33- 35].
One-on-one HIV risk-reduction interventions have been efficacious in several RCTs, reducing self-reported sexual-risk behaviors and biologically confirmed STIs [ 20– 20].
Tumour necrosis factor (TNF) antagonists such as the anti-TNF monoclonal antibodies (mAbs) infliximab (Ifx) and adalimumab (Ada) and the soluble TNF receptor etanercept (Eta) are efficacious in several immune-mediated inflammatory diseases (IMIDs), including rheumatoid arthritis (RA), spondylarthropathies (SA), Crohn's disease (CD), psoriasis arthritis, and juvenile arthritis [ 1- 8].
A number of immunostimulants, such as anti-CTLA4 antibody [1], have been shown to be efficacious in treating established tumors in mice and several of these agents have advanced to clinical trials in humans.
Since several pharmacotherapies have failed to be efficacious in all patients, we also assess the clinical effectiveness of newer agents in relation to existing drugs.
